Xencor, Inc Lessor, Operating Lease, Payment to be Received, Year Three
Xencor, Inc (XNCR) had Lessor, Operating Lease, Payment to be Received, Year Three of $1.83 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears · last filed 2026-08-05
- 2026-06-30: Lessor, Operating Lease, Payment to be Received, Year Three $1.83M.
- 2026-03-31: Lessor, Operating Lease, Payment to be Received, Year Three $1.83M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Three |
|---|---|
| 2026-06-30 | $1.83M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.83M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |